Detection of thyroid stimulating antibodies in sera of patients with Graves’ disease — Clinical and experimental studies

Abstract

Using a new radioreceptor assay with¹²⁵I-staphylococcal protein A as tracing ligand, the authors have determined thyroid stimulating antibody (TSAb) levels in sera of 165 patients with Graves’ disease (GD). The TSAb index (TSAbI) was positive in 91 % (n = 67) of untreated cases, 32 % (n = 28) of cases treated with antithyroid drugs, 28 % (n = 39) of cases in clinical remission, and 90 % (n = 3l) of relapsing cases. TSAbI was found to be negative in all normal controls and negative controls. It was suggested that TSAb existed in sera of most patients with GD, and the variations of TSAb level were correlated with the clinical course of GD. The detection of TSAb may be a useful parameter in monitoring clinical treatment of GD and predicting its relapse.

Keywords

Graves’ disease / thyroid stimulating antibody / radioreceptor assay / staphylococcal protein A

References

[1] TengCS, YeungRT. Changes in thyroidstimulating antibody activity in Graves’ disease with antithyroid drug and its relationship to relapse: a prospective study. J Clin Endocrinol Metab, 1980, 55: 144-7

[2] ZakarijaM, et al.. Clinical significance of assay of thyroid-stimulating antibody in Graves’ disease. Ann Intern Med, 1980, 93: 28-32

[3] HasdistyCA, et al.. The effect of partia thyroidectomy for Graves’ disease on serurm eng-acting thyroid stimulator protector (LATS-P). Clin Endocrinol (Oxf), 1981, 14: 181-8

[4] DaviesTF. Diseases of the TSH receptor. Clin Endocrinol Metab, 1983, 12: 79-100

[5] LangoneJJ, et al.. Use of labeled protein A in quantitative immunochemical analysis of antigens and antibodies. J Immunol Methods, 1982, 51: 3-22

[6] GardasA, et al.. New simple and sensitive method of estimation of antithyroid-plasm-membranes antibodies in serum of patients with autoimmune thyroid disease. Endokrynol Pol, 1982, 33: 295-301

[7] MadecAM, et al.. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves’ disease?. Clin Endocrinol (Oxf), 1984, 21: 247-55